The Real World Study of Zanubrutinib in the Treatment of Chronic Lymphocytic Leukemia in China

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is focused on studying the effectiveness of a medication called Zanubrutinib for treating Chronic Lymphocytic Leukemia (CLL) in patients in China. CLL is a type of cancer that affects the blood and bone marrow, and this study aims to gather real-world information on how well Zanubrutinib works in patients who are either newly diagnosed or experiencing a return of their disease after previous treatments.

To be eligible for this study, participants must be at least 18 years old and have a confirmed diagnosis of CLL that needs treatment. They should have either never received treatment before or have had their CLL return after prior therapies, and they must have been using Zanubrutinib for at least three months. The study is currently not recruiting participants, but once it begins, participants can expect to have their treatment progress monitored, with at least one follow-up appointment during their time on Zanubrutinib. This trial is important as it will help researchers understand how this medication performs in everyday clinical settings.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients aged ≥18 years old
• • 2. Must have a confirmed diagnosis of Chronic Lymphocytic Leukemia (CLL) requiring treatment (iwCLL \[International Workshop on Chronic Lymphocytic Leukemia\] criteria)；
• • 3. Treatment-naïve OR Refractory Recurrence CLL patients who were initiated on Zanubrutinib;
• • 4.Prior or current use of Zanubrutinib for ≥3 months
• • 5.At least one follow-up was recorded during Zanubrutinib treatment
• Exclusion Criteria:
• • -